GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. The company develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
The most recent EPS for GSK plc is $0.25, beating expectations of $0.23.
How did GSK plc GSK's revenue perform in the last quarter?
GSK plc revenue for the last quarter is $0.25
What is the revenue estimate for GSK plc?
According to 8 of Wall street analyst, the revenue estimate of GSK plc range from $8.14B to $7.44B
What's the earning quality score for GSK plc?
GSK plc has a earning quality score of /. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does GSK plc report earnings?
GSK plc next earnings report is expected in 2026-05-05
What are GSK plc's expected earnings?
GSK plc expected earnings is $8.72B, according to wall-street analysts.
Did GSK plc beat earnings expectations?
GSK plc recent earnings of $8.61B does not beat expectations.